Senti Biosciences Advances Logic-Gated CAR-NK Therapy into Pivotal Trial Enrollment

Event summary

  • Senti Biosciences completed enrollment for the Phase 1 clinical trial of SENTI-202, a Logic Gated CAR-NK cell therapy, targeting relapsed or refractory acute myeloid leukemia (R/R AML).
  • Positive clinical data from the trial, presented at ASH 2025, showed deep, MRD-negative, durable complete remissions and a favorable safety profile.
  • The company plans to initiate a pivotal study for SENTI-202 in R/R AML and is exploring expansion into newly diagnosed AML and pediatric AML.
  • SENTI-202 has received both Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation.

The big picture

Senti Biosciences’ progress with SENTI-202 represents a significant advancement in the field of cell and gene therapies for AML, a disease with a high unmet need. The Logic Gated CAR-NK approach aims to overcome limitations of existing therapies by targeting both leukemic blasts and stem cells while minimizing off-target toxicity. The RMAT designation offers a potential advantage in navigating the regulatory pathway, but the success of the pivotal trial will be paramount for long-term commercial prospects.

What we're watching

Regulatory Pathway
The FDA discussions in the first half of 2026 will be critical in determining the speed and scope of SENTI-202’s development, particularly given the RMAT designation’s potential for expedited review.
Clinical Efficacy
The durability of the observed complete remissions in the Phase 1 trial will need to be replicated in a larger, pivotal study to support regulatory approval and commercial viability.
Competitive Landscape
The success of Senti’s Logic Gated CAR-NK approach will be weighed against other emerging AML therapies, including next-generation CAR-T and other cell-based treatments, potentially impacting market share and pricing.

Related topics

Biotechnology